Tarceva Clinical Trials

• Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma.
  ClinicalTrials.gov Identifier: NCT00144976 - Recruiting
  Head and Neck Neoplasms
  
• Erlotinib (Tarceva) vs. Standard Chemotherapy (Paclitaxel and Carboplatin) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and ECOG PS 2
  ClinicalTrials.gov Identifier: NCT00085839 - Active, not recruiting
  Non-Small Cell Lung Carcinoma
  
• A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small-Cell Lung Cancer)
  ClinicalTrials.gov Identifier: NCT00095225 - Active, not recruiting
  Non-Small-Cell Lung Carcinoma; Neoplasm Recurrence, Local
  
• Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients.
  ClinicalTrials.gov Identifier: NCT00137800 - Active, not recruiting
  Stage IIIB or IV Non-Small Cell Lung Cancer
  
• Tarceva and Capecitabine for Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00125021 - Active, not recruiting
  Pancreatic Cancer; Neoplasm Metastasis
  
• A Study to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva for Advanced Non-Small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00130728 - Recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Pilot Study Using Neoadjuvant Chemo-Radiotherapy and Tarceva for Potentially Resectable Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00216307 - Not yet recruiting
  adenocarcinoma of the pancreas
  
• Neoadjuvant Clinical Trial to Evaluate the Efficacy of Avastin and Tarceva for Renal Cell Carcinoma
  ClinicalTrials.gov Identifier: NCT00113217 - Recruiting
  Renal Cell Carcinoma
  
• Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00392665 - Recruiting
  Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  
• Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
  ClinicalTrials.gov Identifier: NCT00187486 - Active, not recruiting
  Glioblastoma Multiforme; Gliosarcoma
  
• BATTLE Program: Tarceva and Targretin in Patients With NSCLC
  ClinicalTrials.gov Identifier: NCT00411632 - Recruiting
  Lung Cancer
  
• A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
  ClinicalTrials.gov Identifier: NCT00294736 - Active, not recruiting
  NSCLC
  
• A Pharmacological Study of Tarceva and Targretin in Stage I-II Lung Cancer
  ClinicalTrials.gov Identifier: NCT00125372 - Recruiting
  Carcinoma, Non-Small Cell Lung Cancer; Non-small cell lung cancer; NSCLC
  
• Tarceva for Good Prognosis, Untreated Advanced NSCLC
  ClinicalTrials.gov Identifier: NCT00204724 - Recruiting
  Non-Small Cell Lung Cancer
  
• BATTLE Program: Tarceva in Previously Treated Subjects With Advanced NSCLC
  ClinicalTrials.gov Identifier: NCT00410059 - Recruiting
  Lung Cancer
  
• Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
  ClinicalTrials.gov Identifier: NCT00522249 - Recruiting
  Carcinoma, Renal Cell
  
• RADIANT: A Study of Tarceva After Surgery With or Without Adjuvant Chemotherapy in NSCLC Patients Who Have EGFR-Positive Tumors
  ClinicalTrials.gov Identifier: NCT00373425 - Recruiting
  Non-Small Cell Lung Cancer
  
• Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
  ClinicalTrials.gov Identifier: NCT00137826 - Active, not recruiting
  Mesothelioma
  
• A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
  ClinicalTrials.gov Identifier: NCT00461708 - Recruiting
  Pancreatic Cancer
  
• Avastin and Tarceva for Upper Gastrointestinal Cancers
  ClinicalTrials.gov Identifier: NCT00350753 - Recruiting
  Esophageal Cancer; Gastric Cancer; Pancreatic Cancer; Cholangiocarcinoma; Gallbladder Cancer
  
• Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
  ClinicalTrials.gov Identifier: NCT00304278 - Recruiting
  Head and Neck Cancer
  
• Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00047762 - Completed
  Colorectal Cancer
  
• Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)
  ClinicalTrials.gov Identifier: NCT00462995 - Recruiting
  Non Small Cell Lung Cancer
  
• Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00072631 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Neoadjuvant, Tarceva, Surgery for Non-Small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00254384 - Recruiting
  Lung Cancer
  
• Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
  ClinicalTrials.gov Identifier: NCT00525525 - Recruiting
  Glioblastoma; Gliosarcoma
  
• Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00385996 - Recruiting
  Carcinoma, Non-Small Cell Lung
  
• A Study with Tarceva and Chemotherapy vs. Chemotherapy alone in Patients with Advanced Lung Cancer
  ClinicalTrials.gov Identifier: NCT00047736 - Completed
  Lung Cancer
  
• Pilot Study Using Neoadj Chemo-Rad & EGFR-Tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00243854 - Recruiting
  Pancreatic Cancer
  
• A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
  ClinicalTrials.gov Identifier: NCT00412217 - Recruiting
  Head and Neck Cancer
  
• Trial of Letrozole Plus OSI-774 (Tarceva) in Post-Menopausal Women With Estrogen Receptor (ER) and/or Progesterone Receptor (PR)-Positive Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00179296 - Recruiting
  Breast Cancer; Neoplasm Metastasis
  
• OSI-774 (Tarceva) Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
  ClinicalTrials.gov Identifier: NCT00040183 - Completed
  Pancreatic Cancer
  
• Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00281021 - Recruiting
  Carcinoma, Non-Small Cell Lung
  
• A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00556322 - Recruiting
  Non-Small Cell Lung Cancer
  
• A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00556712 - Recruiting
  Non-Small Cell Lung Cancer
  
• A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  ClinicalTrials.gov Identifier: NCT00518011 - Recruiting
  Non-Small Cell Lung Cancer
  
• A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
  ClinicalTrials.gov Identifier: NCT00531960 - Recruiting
  Non-Small Cell Lung Cancer
  
• A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
  ClinicalTrials.gov Identifier: NCT00531934 - Recruiting
  Non-Small Cell Lung Cancer
  
• Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
  ClinicalTrials.gov Identifier: NCT00301418 - Recruiting
  Glioblastoma Multiforme; Anaplastic Astrocytoma
  
• Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00466284 - Recruiting
  Non-Small Cell Lung Cancer
  
• Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
  ClinicalTrials.gov Identifier: NCT00418327 - Recruiting
  Malignant Brain Tumor; Brain Stem Glioma,
  
• Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00448240 - Recruiting
  Head and Neck Cancer; Carcinoma, Squamous Cell
  
• TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00563784 - Recruiting
  Non-Small Cell Lung Cancer; Lung Cancer
  
• A Study Evaluating Tarceva in Combination with Avastin versus Avastin Alone in treating Metastatic Renal Cell Carcinoma
  ClinicalTrials.gov Identifier: NCT00081614 - Completed
  Renal Cell Carcinoma; Metastases
  
• A Phase I Study of Single Agent OSI-774 (Tarceva ) Followed by OSI-774 with Temozolomide for Patients with Selected Recurrent/Refractory Solid Tumors, including Brain Tumors
  ClinicalTrials.gov Identifier: NCT00089934 - Recruiting
  Neoplasms
  
• TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00349219 - Recruiting
  Advanced Non-Small Cell Lung Cancer
  
• Erlotinib in Women with Previously Untreated Adenocarcinoma of the Lung
  ClinicalTrials.gov Identifier: NCT00137839 - Recruiting
  Adenocarcinoma; Non-small cell lung cancer
  
• A Study to Evaluate Tarceva in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00091663 - Completed
  Lung Cancer; Non-Small-Cell Lung Carcinoma
  
• Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00123851 - Completed
  Colorectal Cancer; Neoplasm Metastasis
  
• OSI-774 (Tarceva) in Treating Patients with Stage III or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00036647 - Completed
  Carcinoma, Non-Small-Cell Lung
  
• A Phase I/II Trial of an Oral mTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination with an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, Tarceva™) in Patients with Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00179270 - Recruiting
  Metastatic breast cancer
  
• Erlotinib or Placebo Following Chemo/RT in Stage III NSCLC.
  ClinicalTrials.gov Identifier: NCT00153803 - Recruiting
  Carcinoma, Non-Small-Cell Lung; Non-small cell lung cancer; NSCLC
  
• Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
  ClinicalTrials.gov Identifier: NCT00207077 - Completed
  Neoplasms
  
• A Phase II Study of Tarceva and Targretin Oral Capsules in Patients with Advanced Advanced Lung Cancer
  ClinicalTrials.gov Identifier: NCT00125359 - Recruiting
  Carcinoma, Non-Small Cell Lung Cancer; Non-small cell lung cancer; NSCLC
  
• Angiogenic and EGFR Blockade with Curative Chemoradiation for Advanced Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00140556 - Recruiting
  Head and Neck Cancer; Cancer of the Head and Neck; upper aerodigestive tract neoplasms; Pharynx Cancer; Pharynx Neoplasms
  
• Study of Erlotinib in Patients with Non-Metastatic Prostate Cancer with a Rising PSA on Hormone Therapy
  ClinicalTrials.gov Identifier: NCT00148772 - Recruiting
  Non-Metastatic Prostate Cancer; Rising Prostate Specific Antigen (PSA); Andrigen Deprivation Therapy
  
• A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
  ClinicalTrials.gov Identifier: NCT00337883 - Completed
  Glioblastoma
  
• Trial of Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer in Previously Treated Patients
  ClinicalTrials.gov Identifier: NCT00043823 - Suspended
  Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell
  
• A Pharmacokinetic Study of Erlotinib in Cancer Patients with Advanced Solid Tumors, with Normal and Moderately Impaired Hepatic Function
  ClinicalTrials.gov Identifier: NCT00139620 - Completed
  Advanced Solid Tumors
  
• A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00283634 - Terminated
  NSCLC
  
• Phs. II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients W/Advanced Stage or Inoperable Non-Small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00200395 - Suspended
  Non-Small Cell Lung Cancer
  
• Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00063258 - Suspended
  Non-Small-Cell Lung Carcinoma